Table 3.
Top significant associations of SNPs with measles-specific neutralizing antibody titers after MMR vaccination (Caucasians, n=2555a)
| SNP IDb | Gene/Locationc | Major allele | Minor allele | MAFd | P-valuee | Obs.0f | Obs.1f | Obs.2f | Antibody titer Median (IQR) 0g | Antibody titer Median (IQR) 1g | Antibody titer Median (IQR) 2g |
|---|---|---|---|---|---|---|---|---|---|---|---|
| rs2724374 | CD46, intron | T | G | 0.23 | 4.88E-09 | 1462 | 915 | 129 | 924 (414, 1799) | 703 (352, 1418) | 516 (274, 843) |
| rs2761437 | G | A | 0.23 | 6.98E-09 | 1467 | 912 | 127 | 924 (414, 1797) | 702 (349, 1422) | 515 (280, 825) | |
| rs2796265 | T | C | 0.23 | 8.25E-09 | 1467 | 911 | 128 | 924 (414, 1797) | 702 (349, 1420) | 515 (283, 847) | |
| rs2466572 | CD46, intron | C | A | 0.23 | 9.49E-09 | 1464 | 914 | 128 | 924 (414, 1798) | 703 (350, 1418) | 517 (283, 847) |
| rs4844619 | CD46, intron | C | T | 0.23 | 1.05E-08 | 1468 | 914 | 124 | 916 (414, 1794) | 705 (348, 1420) | 526 (283, 864) |
| rs6657476 | CD46, intron | G | T | 0.23 | 1.06E-08 | 1468 | 914 | 124 | 916 (414, 1794) | 705 (348, 1420) | 526 (283, 864) |
| rs2724360 | CD46, intron | T | C | 0.23 | 1.18E-08 | 1461 | 917 | 128 | 924 (414, 1798) | 703 (349, 1418) | 517 (283, 847) |
| rs2761434 | G | A | 0.23 | 1.19E-08 | 1467 | 910 | 129 | 924 (414, 1797) | 702 (349, 1418) | 516 (286, 858) | |
| rs2724384 | CD46, intron | A | G | 0.23 | 1.27E-08 | 1466 | 914 | 126 | 924 (414, 1798) | 702 (354, 1418) | 506 (277, 854) |
| rs4844620 | LOC101929385 | G | A | 0.23 | 1.64E-08 | 1490 | 899 | 117 | 913 (416, 1772) | 701 (345, 1405) | 495 (286, 884) |
| rs4844392 | LOC101929385 | C | G | 0.23 | 1.69E-08 | 1461 | 917 | 128 | 919 (416, 1793) | 702 (344, 1418) | 539 (291, 883) |
| rs11118612 | LOC101929385 | T | A | 0.23 | 1.98E-08 | 1461 | 918 | 127 | 918 (416, 1793) | 702 (346, 1417) | 533 (290, 884) |
| rs1333973 | IFI44L, intron | T | A | 0.33 | 2.10E-08 | 1122 | 1106 | 278 | 942 (422, 1768) | 759 (361, 1448) | 616 (306, 1283) |
| rs66532523 | LOC101929385 | A | C | 0.23 | 2.27E-08 | 1461 | 917 | 128 | 918 (416, 1793) | 702 (345, 1417) | 539 (291, 883) |
| rs56075814 | T | C | 0.23 | 2.34E-08 | 1460 | 918 | 128 | 917 (416, 1794) | 703 (346, 1417) | 539 (291, 883) | |
| rs273259 | IFI44L, missense | A | G | 0.33 | 2.62E-08 | 1118 | 1104 | 284 | 942 (424, 1765) | 757 (356, 1455) | 628 (319, 1284) |
| rs273261 | IFI44L, intron | G | A | 0.34 | 3.41E-08 | 1110 | 1106 | 290 | 950 (428, 1768) | 754 (355, 1441) | 631 (323, 1287) |
| rs4844390 | CD46, intron | A | G | 0.23 | 3.48E-08 | 1478 | 907 | 121 | 919 (414, 1795) | 702 (352, 1417) | 495 (274, 858) |
| rs6669384 | T | C | 0.23 | 3.75E-08 | 1484 | 909 | 113 | 916 (414, 1797) | 703 (349, 1410) | 545 (293, 884) | |
| rs273256 | IFI44L, intron | A | C | 0.35 | 5.10E-08 | 1052 | 1134 | 320 | 958 (435, 1806) | 743 (347, 1448) | 646 (329, 1301) |
| rs273244 | IFI44L, intron | A | T | 0.35 | 6.35E-08 | 1050 | 1136 | 320 | 964 (434, 1807) | 740 (348, 1438) | 646(329, 1311) |
| rs4650590 | IFI44L, 3′UTR | A | G | 0.35 | 6.58E-08 | 1065 | 1131 | 310 | 945 (432, 1808) | 739 (352, 1440) | 646 (329, 1316) |
| rs273238 | G | A | 0.34 | 6.91E-08 | 1108 | 1105 | 293 | 950 (427, 1766) | 758 (355, 1436) | 630 (327, 1299) | |
| rs55935450 | T | A | 0.23 | 6.93E-08 | 1477 | 910 | 119 | 916 (414, 1793) | 700 (347, 1407) | 545 (296, 898) | |
| rs11118668 | C | T | 0.23 | 7.38E-08 | 1477 | 910 | 119 | 916 (414, 1793) | 700 (347, 1407) | 545 (296, 898) | |
| rs61821293 | T | G | 0.23 | 8.51E-08 | 1475 | 910 | 121 | 911 (414, 1790) | 702 (345, 1415) | 561 (299, 884) | |
| rs6693207 | IFI44L, downstream | G | A | 0.35 | 9.28E-08 | 1069 | 1131 | 306 | 956 (434, 1807) | 740 (346, 1447) | 643 (337, 1306) |
| rs273255 | IFI44L, intron | A | T | 0.32 | 1.01E-07 | 1149 | 1095 | 262 | 945 (426, 1769) | 735 (348, 1417) | 634 (328, 1287) |
| rs1318653 | T | C | 0.23 | 1.04E-07 | 1480 | 907 | 119 | 909 (414, 1776) | 702 (345, 1414) | 561 (301, 898) |
a
Reduced to 2506 after excluding subjects with immune outcome data that failed QC
b
SNP identification number
c
Gene/genetic region and SNP location relative to the gene
d
Minor allele frequency
e
P-values, as described in the Online Methods, Statistical Methods
f
Number of subjects with homozygous major allele genotype (0), heterozygous (1) and homozygous minor allele genotype (2)
g
Median neutralizing antibody titer (in miU/mL, with 25% and 75% inter-quartile range/IQR) for subjects with homozygous major allele genotype (0), heterozygous (1) and homozygous minor allele genotype (2)